New insider activity at Surgery Partners ( (SGRY) ) has taken place on March 14, 2025.
Several key executives at Surgery Partners have recently sold significant shares of the company’s stock. CSO Marissa Brittenham sold 3,156 shares, amounting to $76,028. CHRO Danielle Burkhalter sold 1,240 shares for $29,933. CFO David T Doherty parted with 6,733 shares, totaling $161,726. Chief Admin & Dev Officer Jennifer Baldock sold 3,008 shares, worth $72,101. National Group President Harrison R. Bane sold 4,045 shares for $97,727, and American Group President William Trenton Webb sold 2,057 shares, bringing in $49,491.
Recent Updates on SGRY stock
Surgery Partners has experienced notable developments recently, with analysts adjusting their price targets due to the company’s financial performance and strategic outlook. TD Cowen lowered its price target following Q4 results that were generally in line with expectations, but with guidance slightly below, reflecting a cautious stance. Similarly, Benchmark adjusted its price target based on a conservative initial outlook for 2025’s adjusted EBITDA, despite in-line Q4 results and a projected 10% increase in EBITDA at the midpoint. The company announced a delay in filing its annual report due to a change in its accounting firm, though it does not anticipate changes to its financial results. Surgery Partners reported significant revenue and EBITDA growth for 2024, driven by strong organic growth, strategic acquisitions, and a focus on high-acuity specialties like orthopedics. Looking ahead, the company projects continued growth with a strong liquidity position, despite potential risks from legislative changes and transaction costs impacting cash flow.
More about Surgery Partners
YTD Price Performance: 9.91%
Average Trading Volume: 1,356,447
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $3.02B